Rigel entered into an exclusive license and supply agreement with Grifols in January, 2019, to commercialize fostamatinib disodium hexahydrate (fostamatinib) in all potential indications in Europe and Turkey.
In January 2020, Rigel received approval of its marketing authorization application (MAA) for fostamatinib for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments. The product will be marketed in Europe under the brand name TAVLESSE® (fostamatinib) and is the first and only spleen tyrosine kinase (SYK) inhibitor approved in Europe for this indication.
Rigel received an upfront cash payment from Grifols, and is eligible to receive regulatory and commercial milestones, as well as tiered royalties on product net sales.
European Commercial Launch
- Grifols, S.A. is preparing to launch TAVLESSE in the major European markets and will work with the regulatory authorities in the individual countries